Gelonghui, April 15 | Huahai Pharmaceutical (600521.SH) announced that according to preliminary estimates by the financial department, the company's net profit attributable to shareholders of listed companies in the first quarter of 2024 is expected to be between RMB 259.5 million and RMB 285.5 million. Compared with the same period last year (statutory disclosure data), it will increase by about RMB 86.57 million to RMB 112.57 million, an increase of about 50% to 65% over the previous year. The company's net profit attributable to shareholders of listed companies in the first quarter of 2024, after deducting non-recurring profit and loss, is expected to be between RMB 292.2 million and RMB 30.5 million. Compared with the same period last year (statutory disclosure data), it will increase by about 103.65 million yuan to 131.95 million yuan, an increase of about 55% to 70% over the previous year.

During the reporting period, the company achieved significant increases in net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses compared to the same period last year. The main ones were: (1) the continuous introduction and gradual increase of new products, and the initial results of market expansion; (2) deepening sales team fission and organizational restructuring, continuous extension of the market management reach downward, leading the sales team to continue to dig deeper into the market, promote the layout of the global sales network, actively explore emerging markets, improve differentiated service levels, increase customer stickiness, increase the effective market share of products, and increase sales revenue significantly ( 3) Lean management continues to be optimized, technology reform capabilities are continuously improved, and the company's cost control capability and comprehensive strength are further enhanced.